Skip to main content
. 2009 Jul 10;106(30):12471–12476. doi: 10.1073/pnas.0904506106

Fig. 1.

Fig. 1.

Structures, selectivity, and potencies of compounds 1, 2, and 3. (A) Chemical structure of compound 1: (N-(4-(5-(3-(furan-2-ylmethyl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)-2-methoxybenzyloxy)phenyl)acetamide) [NCGC00168126–01]. Chemical structure of compound 2: (N-(4-(5-(3-benzyl-5-hydroxy-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)-2-methoxybenzyloxy)-phenyl)acetamide) [NCGC00161870–01]. Chemical structure of compound 3: 3-(furan-2-ylmethyl)-2-(4-methoxy-3-(phenoxymethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one [NCGC00165237–01]. (B) Cells stably expressing TSHRs, LHCGRs, or FSHRs were exposed to the noted concentrations of compounds 1 and 2 or to a maximally effective concentration of the cognate ligand, TSH (540 nM), LH (34 nM), or FSH (34 nM), respectively, in the presence of 1 mM isobutylmethylxanthine as described in Materials and Methods. After 60 min, the cells were lysed and cAMP levels were measured by ELISA. The data from 3 independent experiments with duplicate samples are shown as the percent of stimulation by the cognate hormone.